I am the Stefanie Spielman Chair in Cancer Imaging and a member of the Translational Therapeutics Program at the OSUCCC – James, where my research focuses on the creation of new molecularly targeted pharmaceuticals visualized in vivo through diagnostic imaging technologies.

I am the holder or co-holder of 38 patents. I developed ProHance™, the first nonionic macrocyclic MRI agent, which has been used in more than 50 million patients. I also invented the first catalysts for the production of technetium radiopharmaceutical kits for the heart and created some of the earliest targeted molecular-imaging agents from monoclonal antibodies.

Most of my projects seek targeted imaging agents that are closely associated biochemically with the therapy so that the patient therapy can be personalized, including co-inventor, first-in-class targeted imaging/therapeutic peptides for prostate and breast cancer; new, self-assembled peptide amphiphiles for MRI imaging; and a new, cell-penetrating peptide for multiple pharmaceutical uses.

I have co-authored more than 100 peer-reviewed research papers appearing in well-respected publications, including Journal of Nuclear Medicine, Molecular Imaging and Biology, and Journal of Clinical Endocrinology & Metabolism. Additionally, he has shared his research in 13 book chapters and in hundreds of presentations at events, such as the International Symposium on Macrocyclic and Supramolecular Chemistry, the Symposium on Molecular Imaging Agents, the Contrast Media Research Symposium and the American Chemical Society.